The RMAT designation for naSPMS is a significant regulatory catalyst that could accelerate the timeline for a second indication. Monitor the Q3 2026 KYSA-8 12-month topline data and completion of the SPS rolling BLA in Q4 2026 as key near-term catalysts. The cash runway into 2028 removes near-term financing risk.
Price Chart
Executive Summary
Kyverna reported Q2 2026 net loss of $0.63 per share, narrower than the $0.67 consensus, with cash burn continuing. The key catalyst is the FDA's RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS), expanding the therapy's regulatory momentum alongside the ongoing rolling BLA submission for stiff person syndrome (SPS). The stock will move on pipeline execution milestones (SPS BLA completion in Q4 2026, gMG enrollment completion mid-2027) rather than the modest earnings beat.
Key Financial Metrics
Key Facts
- FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS), providing accelerated approval pathway eligibility.
- Rolling BLA submission for miv-cel in stiff person syndrome (SPS) is underway; CMC module submitted; completion expected Q4 2026.
- Cash, cash equivalents, and marketable securities were $199.4M as of June 30, 2026, with runway into 2028.
- Net loss per share for Q2 2026 was $0.63, compared to $0.97 in Q2 2025.
- Enrollment in the Phase 3 KYSA-6 trial for generalized myasthenia gravis (gMG) expected to complete by mid-2027.
Financial Impact
Net loss of $38.3M in Q2 2026 vs $42.1M in Q2 2025; cash burn of ~$80M in H1 2026; cash runway into 2028.
Risk Factors
- BLA submission for SPS may face delays or require additional data beyond the single-arm KYSA-8 trial.
- Enrollment in the gMG Phase 3 trial may take longer than expected, pushing out the next catalyst.
- Commercial launch execution in SPS (target 2027) carries significant risk for a first-time commercial biotech.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-344572 |
| Document: kytx-20260811.htm | 0001193125-26-344572 |
| Document: 0001193125-26-344572-index-headers.html | 0001193125-26-344572 |
| Document: 0001193125-26-344572-index.html | 0001193125-26-344572 |
| Document: 0001193125-26-344572.txt | 0001193125-26-344572 |
| 8-K Data (Synthetic) | 0001193125-26-344572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.25 (−10.03%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.25 (−24.96%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.25 (−34.84%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.25 (−34.84%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.25 (−33.77%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.25 (−46.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.25 (+34.88%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.25 (−41.72%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.25 (−48.73%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.25 (−53.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers